BLFS

SEC source: 0001437749-19-007640 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,359

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007471 · rdgdoc.xml · nonDerivative · entry 4

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,875

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019.

SEC source: 0001437749-19-007471 · rdgdoc.xml · derivative · entry 6

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 10,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007471 · rdgdoc.xml · derivative · entry 5

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,928 shares

Expires 2023-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007471 · rdgdoc.xml · nonDerivative · entry 3

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-007471 · rdgdoc.xml · nonDerivative · entry 2

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007471 · rdgdoc.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007470 · rdgdoc.xml · derivative · entry 3

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 3,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16.

SEC source: 0001437749-19-007470 · rdgdoc.xml · nonDerivative · entry 2

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,074

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018.

SEC source: 0001437749-19-007470 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007641 · rdgdoc.xml · derivative · entry 3

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007641 · rdgdoc.xml · nonDerivative · entry 2

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,388

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-007641 · rdgdoc.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,388

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-007127 · rdgdoc.xml · derivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,798

Underlying: Common Stock · 7,088 shares

Expires 2020-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011.

SEC source: 0001437749-19-007127 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,014

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-007127 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-005542 · rdgdoc.xml · derivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-19-005542 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,359

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.80 to $19.87 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-005542 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,359

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-005089 · rdgdoc.xml · derivative · entry 3

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,000

Underlying: Common Stock · 3,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16.

SEC source: 0001437749-19-005089 · rdgdoc.xml · nonDerivative · entry 2

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,074

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.61 to $16.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-005089 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-005090 · rdgdoc.xml · derivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,886

Underlying: Common Stock · 7,088 shares

Expires 2020-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011.

SEC source: 0001437749-19-005090 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,014

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-005090 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-003528 · rdgdoc.xml · derivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,776

Underlying: Common Stock · 15,776 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003528 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,359

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003527 · rdgdoc.xml · derivative · entry 2

Foster Karen A. · CIK 0001683151 · Vice President, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,668

Underlying: Common Stock · 11,668 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003527 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Vice President, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,585

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003529 · rdgdoc.xml · derivative · entry 2

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,491

Underlying: Common Stock · 6,491 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003529 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,074

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003526 · rdgdoc.xml · derivative · entry 2

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,217

Underlying: Common Stock · 8,217 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003526 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,384

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003525 · rdgdoc.xml · derivative · entry 2

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,598

Underlying: Common Stock · 16,598 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003525 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,620

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003524 · rdgdoc.xml · derivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,497

Underlying: Common Stock · 35,497 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-19-003524 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,014

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001437749-19-003202 · rdgdoc.xml · derivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-19-003202 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,583

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.19 to $17.35 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-003202 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-002786 · rdgdoc.xml · derivative · entry 3

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 3,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16.

SEC source: 0001437749-19-002786 · rdgdoc.xml · nonDerivative · entry 2

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,583

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018.

SEC source: 0001437749-19-002786 · rdgdoc.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-002787 · rdgdoc.xml · derivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,974

Underlying: Common Stock · 7,088 shares

Expires 2020-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option vested equally over four years commencing on February 5, 2011.

SEC source: 0001437749-19-002787 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,517

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-002787 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-19-001007 · rdgdoc.xml · derivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.

SEC source: 0001437749-19-001007 · rdgdoc.xml · nonDerivative · entry 2

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,583

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $12.51 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-19-001007 · rdgdoc.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-012378 · rdgdoc.xml · derivative · entry 6

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,714 shares

Expires 2019-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.